[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"visceral-adipose-tissue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:visceral-adipose-tissue":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100628922","impact-of-visceral-adiposity-on-postoperative-atrial-fibrillation-after-cabg-100628922",false,"NCT07467941","Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After CABG","Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG): A Prospective Observational Study","Inclusion Criteria:\n\n* Elective isolated coronary artery bypass graft surgery (on-pump)\n* Age ≥18 years, planned prospectively in 300 patients\n\nExclusion Criteria:\n\n* Patients requiring urgent or emergency surgery\n* Off-pump coronary artery bypass graft surgery\n* Surgeries other than isolated coronary artery bypass graft\n* Patients in whom abdominal ultrasound measurement cannot be performed (e.g., due to severe deformity, wounds, edema)\n* Active malignancy\n* eGFR \\\u003C30 mL\u002Fmin\n* Advanced-stage chronic obstructive pulmonary disease (COPD)\n* Preoperative atrial fibrillation or atrial flutter\n* Patients who do not provide written informed consent for the study","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","Obesity has become a major public health problem in both developed and developing countries, with a continuous increase particularly since the 1980s. Moreover, it is a well-established metabolic risk factor for diabetes mellitus, hypertension, and various types of cancer, as well as cardiovascular diseases such as heart failure and coronary artery disease. Body mass index (BMI) is calculated by dividing body weight in kilograms by the square of height in meters and is widely used as an indicator of obesity. However, BMI does not quantitatively reflect body fat distribution and fails to account for components such as skeletal muscle and bone mass. Therefore, interest in assessing body fat distribution has increased, and in recent years, studies evaluating the correlation between anthropometric, biochemical, and anatomical measurements and clinical outcomes have become more frequent. In particular, it is acknowledged that abdominal obesity cannot be accurately represented by BMI alone and is primarily associated with visceral adipose tissue (VAT). The aim of this study is to evaluate the association between preoperative visceral and subcutaneous adipose tissue measurements (VAT and SAT), assessed by ultrasonography in patients scheduled for open-heart surgery, and the development of postoperative atrial fibrillation.",[24,25,26],"CABG","Visceral Adipose Tissue","Atrial Fibrillation (AF)",[26,25,24],"NOT_YET_RECRUITING","2026-03-08",{"date":31,"type":32},"2026-03-12","ACTUAL",{"date":34,"type":20},"2026-04-01",{"date":36,"type":20},"2027-01-22",{"name":38,"class":39},"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","OTHER_GOV",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100595021","nutritional-oleic-acid-modulation-of-adipose-cholesterol-metabolism-in-patients-living-with-obesity-100595021","NCT07027033","Nutritional Oleic Acid Modulation of adIpose Cholesterol Metabolism in Patients Living With Obesity","NAMICO","Inclusion Criteria:\n\n* • Individual who has given informed consent.\n\n  * Female adult aged between 18 and 60 years (included).\n  * Patient with obesity at inclusion, meeting the HAS criteria for bariatric surgery eligibility: BMI ≥ 35 kg\u002Fm² associated with a comorbidity or BMI \\> 40 kg\u002Fm².\n  * European origin: For this pilot study, we need to reduce variability factors and focus the research on women of European descent only (having both parents identified by the patient as of European origin).\n  * Effective contraception if sexually active, or abstinence, or menopause (criterion required for bariatric surgery).\n  * Presenting at inclusion with at least two clinical criteria of insulin resistance according to the definition of the International Diabetes Federation (IDF):\n\n    * Dysglycemia (fasting glucose ≥ 100 mg\u002FdL, glucose intolerance, or type 2 diabetes).\n    * Hypertension (≥ 130\u002F85 mm Hg).\n    * Low HDL-cholesterol (\\\u003C 50 mg\u002FdL).\n    * Elevated triglycerides (≥ 150 mg\u002FdL).\n  * Affiliated with a social security system or a beneficiary of such a system.\n  * Bariatric surgery performed at Nantes University Hospital (CHU de Nantes).\n\nExclusion Criteria:\n\n* • Modification of diabetes treatment within the past month.\n\n  * Ongoing or planned insulin therapy before bariatric surgery.\n  * Modification of lipid-lowering treatment within the past three months.\n  * Systemic corticosteroid therapy.\n  * Antiviral therapy (HIV).\n  * Dietary supplementation affecting lipid metabolism, including proactive margarine, Danacol, polyunsaturated fatty acid supplementation, or any other substance identified by the investigator.\n  * Exocrine pancreatic insufficiency.\n  * Pregnancy or breastfeeding.\n  * History of organ transplantation.\n  * Individual deprived of liberty or under legal protection (guardianship or trusteeship).\n  * Any clinical condition in which the investigator considers that inclusion in the study may harm the patient's health or compromise the proper conduct of the study.\n  * Participation in other clinical trials, except for non-interventional studies and research on surgical techniques or postoperative strategies.\n\n    * Type I, monogenic or secondary diabetes.","FEMALE","60 Years",{"count":50,"type":20},40,"INTERVENTIONAL",[53],"NA","Disruption of white adipose tissue (WAT) homeostasis during obesity is central to the development of associated cardiometabolic complications. Dietary supplementation with oleic acid in obese patients can limit these complications. Experimental data, obtained in preclinical models, suggest that the beneficial effects of oleic acid may protect the TAB by increasing cholesterol esterification. The NAMICO study aims to test this hypothesis using TAB biopsies collected from obese patients undergoing bariatric surgery who had previously undergone dietary enrichment with either a conventional oil or an oil rich in oleic acid.",[56,25,57,58],"Obesity","White Adipose Tissue Inflammation","Subcutaneous Adipose Tissue",[60,61,62,63,64],"obesity","visceral adipose tissue","adipocyte dysfunction","oleic acid","cholesterol esterification","RECRUITING","2026-01-13",{"date":68,"type":32},"2026-01-15",{"date":70,"type":32},"2025-07-15",{"date":72,"type":20},"2028-07-01",{"name":74,"class":75},"Nantes University Hospital","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":76},"100528765","ius-combined-with-vat-predicts-anti-tnf--efficacy-in-patients-with-ibd-a-prospective-study-100528765","NCT06165029","IUS Combined With VAT Predicts Anti-TNF-α Efficacy in Patients With IBD: a Prospective Study","Intestinal Ultrasound Combined With Visceral Adipose Tissue Predicts Anti-TNF-α Efficacy in Patients With Inflammatory Bowel Disease: a Prospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years;\n* Patients with newly diagnosed or relapsed active IBD;\n* Anti-TNF-α monotherapy is proposed to be applied within 1 month after baseline endoscopy;\n* No history of abdominal surgery;\n* Clearly understand, voluntarily participate in the study, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to anti-TNF-α therapy: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III\u002FIV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;\n* Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;\n* Hypersensitivity to the components of SonoVue contrast media.","80 Years",{"count":86,"type":20},50,"Inflammatory Bowel Disease (IBD) is a chronic recurrent nonspecific inflammatory disease of the intestinal tract that can involve multiple organs and systems, mainly including Crohn's disease (CD) and ulcerative colitis (UC). Recurrent disease episodes lead to high rates of disability and unemployment, resulting in a heavy social and economic burden. Currently, the main therapeutic agents for IBD include aminosalicylic acid preparations, glucocorticoids, immunosuppressive agents, and biologic agents, e.g. tumor necrosis factor-a (TNF-a) inhibitors, ustekinumab, etc., with TNF-a inhibitors being the most commonly used in IBD.\n\nThe latest guidelines and expert consensus on the diagnosis and management of IBD clearly recommend the use of anti-TNF-a agents. However, not all patients are satisfied with the efficacy of anti-TNF-a agents, and studies have shown that up to 33.7% of responders to induction therapy experience secondary loss of response within a year of starting treatment. Patients remain at risk of poor efficacy or treatment failure with these drugs. Therefore, effective prediction of drug efficacy in patients with IBD is an urgent clinical problem, and the discovery of highly sensitive and specific assays that can identify patients most likely to benefit from treatment as well as those most likely to experience a loss of response is important for guiding clinical therapeutic strategies.\n\nCurrently, there are no relevant studies at home or abroad on the combination of intestinal ultrasound (IUS) with visceral adipose tissue (VAT) to predict the response to anti-TNF-a therapy in IBD patients. Therefore, the investigators propose for the first time that IUS combined with VAT is used as a method to predict the efficacy of anti-TNF-a therapy in IBD patients and to further guide the development of individualized treatment plans.",[89,90,25,91,92],"Inflammatory Bowel Diseases","Intestinal Ultrasound","TNF-α","Predictors","2024-08-24",{"date":95,"type":32},"2024-08-27",{"date":97,"type":32},"2023-11-22",{"date":99,"type":20},"2025-03-30",{"name":101,"class":75},"The Third Xiangya Hospital of Central South University"]